Efficacy News and Research

RSS

Study highlights pulmonary artery denervation as a key intervention for pulmonary hypertension

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for pulmonary hypertension (PH), a condition that places patients at risk for right heart failure and death.

8 Apr 2025

Tolebrutinib shows promise for treating non-relapsing secondary progressive multiple sclerosis

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

8 Apr 2025

New drug compound prevents long COVID symptoms in mice

Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.

8 Apr 2025

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves neuron health in animal models of Alzheimer's disease, according to a new Northwestern University study.

8 Apr 2025

Global research initiative aims to optimize post-cardiac arrest ICU care

Researchers at 60 different intensive care units around the world are seeking to establish methods to expedite and improve post-cardiac arrest recovery at ICUs.

8 Apr 2025

Cannabis extract can improve behavior of children and teens with autism spectrum disorder

New research presented at the 2025 European Congress of Psychiatry reveals that the use of cannabidiol (CBD) cannabis extract can lead to meaningful benefits and improve the behavior of children and adolescents with autism spectrum disorder (ASD).

8 Apr 2025

Semaglutide linked to higher risk of vision problems, FDA data analysis shows

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher reporting rate of vision impairment. The findings call for further study into the ocular risks of this widely prescribed diabetes and weight loss drug.

8 Apr 2025

GP38 identified as key viral toxin and vaccine target in Crimean-Congo hemorrhagic fever virus research

A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with scientists from the Albert Einstein College of Medicine and the University of California-Berkeley have advanced discoveries surrounding the viral glycoprotein GP38 expressed by the Crimean-Congo hemorrhagic fever virus (CCHFV).

8 Apr 2025

Paxlovid found ineffective for long COVID relief in new trial

Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving long COVID symptoms, according to a new study published in The Lancet Infectious Diseases on April 3.

7 Apr 2025

High cholesterol may not signal heart disease risk in metabolically healthy people

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, in collaboration with researchers across multiple institutions, has published a new study that challenges the long-held belief that high cholesterol correlates and even directly causes coronary artery disease, or plaque buildup in the arteries in metabolically healthy individuals.

7 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Drug-carrying DNA aptamers offer dual action against leukemia stem cells

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana-Champaign report.

3 Apr 2025

Rutgers researchers develop promising new oral antiviral for COVID-19

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

3 Apr 2025

Study sheds light on how major cancer gene influences the success of PARP inhibitors

A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.

3 Apr 2025

Clinical trial demonstrates safety of targeted treatment approach for deadly brain tumor in children

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators.

3 Apr 2025

New CT-based score helps predict need for repeat sinus surgery

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis.

3 Apr 2025

Breakthrough research identifies small peptide for psoriasis treatment

Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis, when applied topically in an emollient cream.

3 Apr 2025

Gut bacteria may reduce the effectiveness of common medications

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

3 Apr 2025

NUZ-001 shows positive results in human 3D brain model

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to advise that results from an independent study undertaken in collaboration with Tessara Therapeutics (“Tessara”) will be presented by the group’s Principal Scientist and Alzheimer’s Disease expert, Dr Mark Greenough at the AD/PD 2025 Advances in Sciences & Therapy conference on April 2nd to 3rd.

3 Apr 2025

Unraveling resistance to CDK4/6 inhibitors in ovarian cancer

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies.

3 Apr 2025